These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 3731920)
1. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients. Rolston K; Alvarez ME; Hoy JF; LeBlanc B; Ho DH; Bodey GP Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920 [TBL] [Abstract][Full Text] [Related]
2. [In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals]. Sader HS; Mendes CM; Montelli A; Sampaio J; Segura AJ; Kesselring GL; Costa L; Ribeiro JE; Mamizuka E; Mimiça I Rev Assoc Med Bras (1992); 1998; 44(4):283-8. PubMed ID: 9852647 [TBL] [Abstract][Full Text] [Related]
3. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group. Spencer RC Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900 [TBL] [Abstract][Full Text] [Related]
4. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. Cheng AF; Ling TK; Lam AW; Fung KS; Wise R J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefpirome (HR810) against antibiotic-resistant gram-positive and gram-negative bacteria including organisms with inducible resistance. Murray PR; Niles AC Diagn Microbiol Infect Dis; 1986 Jan; 4(1):53-63. PubMed ID: 3632921 [TBL] [Abstract][Full Text] [Related]
6. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000 [TBL] [Abstract][Full Text] [Related]
8. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe. International Study Group. Verbist L Scand J Infect Dis Suppl; 1993; 91():14-24. PubMed ID: 8290899 [TBL] [Abstract][Full Text] [Related]
9. [Activity of cefpirome against bacteria isolated from hospitalized patients]. Fernández A; Herran I; de Mier C; Marcenac FM Medicina (B Aires); 1989; 49(4):373-8. PubMed ID: 2487748 [TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies. Sader HS; Jones RN Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):675-9. PubMed ID: 7813503 [TBL] [Abstract][Full Text] [Related]
11. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres. Reeves DS; Bywater MJ; Holt HA J Antimicrob Chemother; 1993 Mar; 31(3):345-62. PubMed ID: 8486569 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients. Rolston KVI; Jamal MA; Nesher L; Shelburne SA; Raad I; Prince RA Int J Antimicrob Agents; 2017 Apr; 49(4):416-421. PubMed ID: 28257904 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients. Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP Chemotherapy; 1986; 32(6):506-14. PubMed ID: 3100147 [TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime. Bauernfeind A J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170 [TBL] [Abstract][Full Text] [Related]
15. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. Pillar CM; Aranza MK; Shah D; Sahm DF J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646 [TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients. Rolston KV; Bodey GP Infection; 1986; 14(3):139-41. PubMed ID: 3733227 [TBL] [Abstract][Full Text] [Related]
18. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents. Bell JM; Turnidge JD; Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610 [TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial activities of FK037: a new parenteral cephalosporin. Inoue K; Inoue E; Mitsuhashi S Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206 [TBL] [Abstract][Full Text] [Related]
20. The antimicrobial activity in vitro of cefpirome and 6 other beta-lactam antibacterial agents against clinical isolates. Yoshimura H; Kosaka Y; Hayashi T; Kawahara S Jpn J Antibiot; 1993 Oct; 46(10):877-83. PubMed ID: 8254889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]